

REMARKS

Amendment of the Claims

Claims 1-18 have been withdrawn as being directed to non-elected inventions.

Applicants reserve the right to pursue these claims in a Continuation or Divisional application.

Claim 19 has been amended to recite “[a] method of identifying T cells in a sample that become activated in the presence of vaccinia or variola virus, comprising contacting the T cells with a polypeptide selected from the group consisting of: peptide 74A (SEQ ID NO: 1), peptide 165 (SEQ ID NO: 2), an immunogenic mutant or fragment thereof and a combination thereof, wherein activation of the T cells by the polypeptide indicates that the T cells become activated in the presence of vaccinia or variola virus.” Support for this amendment can be found, for example, at page 19, lines 9-16 of the specification.

Claims 21, 28 and 33 have been amended to recite “wherein the cytokine assay is an ELISPOT assay and the flow cytometry assay is a tetramer staining assay.” Support for this amendment can be found, for example, at page 20, lines 24-25 of the specification.

Claim 24 has been amended to correct a typographical error.

The amended claims are supported by the subject application as originally filed.

CONCLUSION

In view of the above amendments and remarks, it is believed that all claims are in condition for allowance, and it is respectfully requested that the application be passed to issue. If the Examiner feels that a telephone conference would expedite prosecution of this case, the Examiner is invited to call the undersigned.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Eric M. Balicky  
Registration No. 57,020  
Telephone: (978) 341-0036  
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: *March 21, 2006*